Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Standard
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). / Maffini, Enrico; Labopin, Myriam; Beelen, Dietrich Wilhelm; Kroeger, Nicolaus; Arat, Mutlu; Wilson, Keith M O; Bay, Jacques-Olivier; Ganser, Arnold; Martin, Hans; Passweg, Jakob; Kottaridis, Panagiotis D; Yakoub-Agha, Ibrahim; Porras, Rocio Parody; Wagner, Eva Maria; Esteve, Jordi; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad.
In: BONE MARROW TRANSPL, Vol. 57, No. 10, 10.2022, p. 1556-1563.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
AU - Maffini, Enrico
AU - Labopin, Myriam
AU - Beelen, Dietrich Wilhelm
AU - Kroeger, Nicolaus
AU - Arat, Mutlu
AU - Wilson, Keith M O
AU - Bay, Jacques-Olivier
AU - Ganser, Arnold
AU - Martin, Hans
AU - Passweg, Jakob
AU - Kottaridis, Panagiotis D
AU - Yakoub-Agha, Ibrahim
AU - Porras, Rocio Parody
AU - Wagner, Eva Maria
AU - Esteve, Jordi
AU - Lanza, Francesco
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.
AB - Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.
KW - Acute Disease
KW - Adult
KW - Bone Marrow
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Leukemia, Myeloid, Acute/therapy
KW - Neoplasm, Residual
KW - Neoplasms, Second Primary
KW - Recurrence
KW - Retrospective Studies
KW - Transplantation Conditioning
U2 - 10.1038/s41409-022-01748-w
DO - 10.1038/s41409-022-01748-w
M3 - SCORING: Journal article
C2 - 35835997
VL - 57
SP - 1556
EP - 1563
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 10
ER -